Wednesday, May 15, 2013 7:58:20 AM
This is what SLP is all about... Saving time and money for the drug discovery industry.
Simulations Plus Software Used in Regulatory Submittals
Simulations Plus, Inc. (SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that results of simulations using its GastroPlus™ software have been submitted to major regulatory agencies as part of applications by its customers.
John DiBella, vice president of marketing and sales for Simulations Plus, noted, “The first submittal to a regulatory agency was reported by Pfizer in 2008, which resulted in Pfizer being allowed to forego a human trial after GastroPlus simulations showed that it would not be necessary. In the past 12 months, four additional customers have submitted simulation results to the U.S. Food and Drug Administration (FDA), the European Medical Agency (EMA), and the British Medical Health Regulatory Agency (MHRA). Each of these involved a consulting contract with Simulations Plus to assist the sponsor with the GastroPlus simulations and model development. Simulations Plus also provided assistance in preparation of the submittals to the regulatory agencies. The acceptance of simulation results by these agencies is an indication of the growing importance of simulation and modeling technology in pharmaceutical research and development.”
Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “The four submittals John describes resulted in:
1. Eliminating a clinical trial to demonstrate that fasted and fed states would not produce significantly different results for the absorption of the drug candidate.
2. Identifying the particle size specification for a re-engineered product to ensure bioequivalence to an existing product.
3. Explaining the variations observed in different formulations.
4. Scaling complex processes involving metabolism and carrier-mediated transport from adult to pediatric/neonate populations.
These four submissions signal a developing trend for the use of simulation and modeling results to reduce the cost and time to bring new drug products to market. Note that these four involved Simulations Plus consulting services. A number of other submittals have been made by sponsors on their own. Regulatory agencies in the U.S., Europe, China, and Japan all have GastroPlus for their internal use, so sponsors can submit GastroPlus input files to these agencies to make evaluation of results fast and convenient. In time, we believe other sponsors will increasingly utilize powerful simulation software to help streamline the regulatory process and provide regulators with accurate data for evaluation purposes.”
The only place where success comes before work is in the dictionary
Recent SLP News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/07/2024 08:20:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/07/2024 08:20:26 PM
- U.S. FDA Renews DILIsym® Software Licenses for 7th Year • Business Wire • 04/04/2024 12:30:00 PM
- Exxon Mobil Forecasts Earnings Decline, Twilio Seeks Board Tenure Changes, and More News • IH Market News • 04/04/2024 11:30:20 AM
- Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results • Business Wire • 04/03/2024 08:34:00 PM
- U.S. Futures Dip in Pre-Market, May WTI and June Brent Crude Prices Edge Higher • IH Market News • 04/03/2024 11:11:59 AM
- Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date • Business Wire • 03/20/2024 08:06:00 PM
- Simulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum • Business Wire • 03/13/2024 12:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/06/2024 09:07:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:22:46 PM
- Simulations Plus and the University of Bath Awarded New FDA Grant • Business Wire • 03/05/2024 01:30:00 PM
- Simulations Plus Extends Collaboration with Major Toxicology Research Agency • Business Wire • 02/15/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 02:15:43 PM
- Simulations Plus Launches Corporate Development Initiative • Business Wire • 02/13/2024 02:15:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 09:59:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:01:30 PM
- Simulations Plus to Participate in Upcoming Healthcare Conferences • Business Wire • 02/06/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 10:04:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:42:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:40:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:39:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:37:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:34:53 PM
- Simulations Plus Releases GastroPlus® Version 9.9 • Business Wire • 01/30/2024 01:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:02:44 PM
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM